All News
Ross et al. Ultrasound assessed Optic nerve sheath measurement in GCA. Previously shown increased in GCA. Here decreases with treatment shown in 9 patients Abstr#1650 #ACR23 @RheumNow https://t.co/fcrS4tT6U0 https://t.co/ylnPKzdUe0
Richard Conway ( View Tweet)
In PS-matched study, no significant difference in respiratory hospitalisation or death between RA-ILD patients on non-TNFi/JAKi vs. TNFi. This finding does not support systematic avoidance of TNFi in RA-ILD, England B Abst#1582 #ACR23 #ACRBest @RheumNow https://t.co/1zVjMWNZZS https://t.co/d8TRIvGaIe
Dr. Antoni Chan ( View Tweet)
Fate of ANA+/UCTD
A#1449 #ACR23 @RheumNow
207 asymptomatic ANA+ or UCTD followed
- <10% progress to SARD, 90% did not
Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1)
Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations
Eric Dein ( View Tweet)
Abst#1583 SMART study: Split dose qwk MTX (10 mg QAM, 15 mg QPM) may have better efficacy compared to 25 mg single dose qwk MTX. RCT 253 RA patients: split dose had better DAS score, less likely to add other DMARDS, but slight⬆️in LFTs. #Plenary #ACR23 @rheumnow #ACRbest
TheDaoIndex KDAO2011 ( View Tweet)
Visit RheumNow's Booth at #ACR23
https://t.co/7HuNpWtf0M https://t.co/INtMGvEkA3
Dr. John Cush RheumNow ( View Tweet)
Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0
Richard Conway ( View Tweet)
FDG-PET uptake at baseline in GCA predicts future risk of future thoracic aneurysm
In print here: https://t.co/2SQm18y6zP
Could this help stratify aneurysmal screening?
#ACR23 ABST1647 @RheumNow https://t.co/p1Dhkm2WTX
David Liew drdavidliew ( View Tweet)
It's OK to use TNFi in RA-ILD!
VA study 1000+ pts using Target Trial Emulation framework: TNFi vs nonTNFi biologics/JAKi followed for 3 years. NO differences in respiratory hospitalizations or deaths or all cause mortality. abst#1582 #ACR23 #ACRbest @rheumnow https://t.co/aI2SmMrLPE
TheDaoIndex KDAO2011 ( View Tweet)
Wolfgang Schmidt presenting @eular_org large vessel vasculitis imaging recommendations at #ACR23, acknowledging @ACRheum on the way.
Great to see a master (& a new ACR Master) navigate with clarity, uniting different sides of the Atlantic.
@RheumNow https://t.co/hyAcX8GSWf
David Liew drdavidliew ( View Tweet)
What do we see in GCA, with serial PET/CT after five years?
In this Australian cohort:
cranial uptake disappears
extra-cranial uptake sometimes emerges (but not for pts on DMARDs)
Still understanding the trajectory of smouldering activity
@tonysammel #ACR23 ABST1645 @RheumNow https://t.co/mKB3mjBuBt
David Liew drdavidliew ( View Tweet)
Factors predicting fatigue in RA differ by disease activity.
Synovial lining hyperplasia and synovial lymphocytic inflammation on histology were key factors.
@rheumnow #ACR23 session 13M148 https://t.co/yPBZX2Rxft
Bella Mehta bella_mehta ( View Tweet)
RA-ILD: the study that exonerates TNFi ?
TNFi vs. other BioDMARDs/JAK do not increase risk of death or hospitalization over 1 and 3 yrs follow up.
No subgroups stand out
VHA cohort, 50% smokers
No info on ILD patterns or disease trajectory
ABST1582 @RheumNow #ACR23 https://t.co/frv16oRLqv
Aurelie Najm ( View Tweet)
Lovering et al. Synergestic effect of RA and CVD on dementia risk. 35% increased risk RA, 89% increased risk RA+CVD. Abstr#1628 #ACR23 @RheumNow https://t.co/Brj8XrG2o4
Richard Conway ( View Tweet)
#ClinicalPearl or #pathology pearl? Using synovial #biopsies to guide therapy in #RA #RCTs is a reality. But likely #fibrotic #phenotype won’t respond and #lympho_myeloid has more RA damage. #ACR23 session 13M140 #Precision #medicine #ACRbest @ACRheum @RheumNow https://t.co/DmI9dNpu8w
Janet Pope ( View Tweet)
PET/CT real-world performance in GCA diagnosis, Sydney @tonysammel:
comparable to other modalities
can optimize for sen or spec based on managing equivocal results
?some steroid confounding
but definitely one of 3 complementary imaging options for GCA
#ACR23 ABST1646 @RheumNow https://t.co/FvdLMvpqEU
David Liew drdavidliew ( View Tweet)
#ACR23 Abstr#1634 Promising therapy for two #Sjogren groups: 1 (high ESSDAI & ESSPRI) & 2 (low ESSDAI, high ESSPRI). Phase 2 RCT of Iscalimab (anti-CD40ab) showed more ISC-treated pts met the primary endpoint (ESSDAI and ESSPRI changes at WK24) vs PBO. Going to Phase 3 @RheumNow https://t.co/3bN3IS1zCO
Md Yuzaiful Md Yusof ( View Tweet)
@Dr_K presenting long COVID data from FORWARD RA.
These pts had some symtoms before COVID!- More comorbidites, depression patient reported scores, fibromyalgia but no different DMRD use.
PHQ8 and wodepread paid were the most important PROMs @RheumNow
#ACR23 https://t.co/JaWc4oDnaI
Bella Mehta bella_mehta ( View Tweet)
Window of opportunity in PsA
Higher time to diagnosis in
-female
-higher enthesitis
-less swollen joints
-lower CRP
If diag > 52 wks, over 3 yrs
Less MDA, less remission
Worse HAS-DI, PSAID
Same Rx progression
No diff between <12 wk & 12-52 wk
@RheumNow #ACR23 ABST1641 https://t.co/Ek1CDFwENg
Aurelie Najm ( View Tweet)
#Precision #Medicine in RA RCTs. Treat w right drug at right time?
Possible problems -sample variation on synovial #bx, some won’t respond ex fibrotic phenotype variable drug distribution/resistance. AI is helping to separate Pts #ACR23 @ACRheum @RheumNow 13M140 https://t.co/D7NxpM4YNw
Janet Pope ( View Tweet)
Michaud et al. RA patients with long COVID had more fibromyalgia pre-COVID (41% vs 13%), higher rates of pain, depression, and worse PROs pre-COVID. Authors suggest long COVID may partially reflect pre-existing illness Abstr#1629 #ACR23 #ACRbest @RheumNow https://t.co/mrcGWrSD6c https://t.co/YiGCbvBDtn
Richard Conway ( View Tweet)